ArticleAnnals of medicine and surgery (2012)2025
Rare case of ovarian Sertoli-Leydig cell tumor in an adolescent: a case report.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and Importance: Androgen-producing tumors are rare in females, typically arising from the ovaries or adrenal glands. Sertoli-Leydig cell tumors (SLCTs) are uncommon sex cord-stromal ovarian tumors that cause hyperandrogenism, leading to virilization symptoms such as hirsutism, deep voice, and amenorrhea. Their rarity and similarity with other androgen-secreting conditions make diagnosis challenging. This case report describes an SLCT in a 16-year-old girl, underscoring the value of early diagnosis and fertility-sparing surgery. Case Presentation: A 16-year-old girl presented with secondary amenorrhea, hirsutism, and voice deepening. Hormonal workup revealed elevated testosterone and low sex hormone-binding globulin. Imaging identified a solid mass in the left ovary. Adrenal causes were excluded via hormonal assays and imaging. The patient underwent a laparotomy with left salpingo-oophorectomy. Histopathology confirmed a moderately differentiated SLCT, and immunohistochemistry was positive for inhibin and calretinin. Postoperative CT showed no metastasis. She required no chemotherapy and remained under regular follow-up. Clinical Discussion: SLCTs represent less than 1% of ovarian tumors and primarily affect young women. They often present with signs of androgen excess. Diagnosis relies on clinical, hormonal, imaging, and histological data. DICER1 gene mutations are frequently associated. Surgical excision is the standard treatment, with fertility-sparing options preferred in early stages. Chemotherapy is reserved for advanced or poorly differentiated cases. Conclusion: SLCT is a rare but treatable ovarian tumor. Early detection of androgen excess is crucial. Surgery is effective, and fertility can be preserved. Larger registries are needed to enhance disease understanding and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.